Lisata Therapeutics (LSTA) vs Oragenics (OGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Oragenics is the larger company by market cap ($708,377 vs $647,451), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LSTA | OGEN |
|---|---|---|
| Share price | $0.8989 | $0.157 |
| Market cap | $647.45K | $708.38K |
| 1-day change | -1.22% | -8.72% |
| YTD return | -51.67% | — |
| 1-year return | -54.14% | — |
| 5-year return | -93.89% | — |
| EPS (TTM) | $-28.20 | $-1.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $170.00K | — |
| Revenue growth (YoY) | -83.00% | — |
| Net income (latest FY) | $-16.59M | $-9.84M |
| Operating margin | -10711.18% | — |
| Net margin | -9756.47% | — |
| 52-week high | $76.05 | $1.11 |
| 52-week low | $0.85 | $0.13 |
| Distance from 52-week high | -98.82% | -85.86% |
| Analyst consensus | none | — |
| Average volume | 13.46K | 849.30K |
| Shares outstanding | 720.27K | 4.51M |
| Employees | 21 | 3 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Lisata Therapeutics
LSTA stock →Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Oragenics
OGEN stock →Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
LSTA vs OGEN FAQ
Which is bigger, Lisata Therapeutics or Oragenics?
Oragenics (OGEN) is larger, with a market capitalization of $708.38K compared with $647.45K for Lisata Therapeutics (LSTA).
Are Lisata Therapeutics and Oragenics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.